Dianthus Therapeutics (DNTH) Cash & Current Investments (2017 - 2025)
Historic Cash & Current Investments for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $402.6 million.
- Dianthus Therapeutics' Cash & Current Investments rose 4321.6% to $402.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $402.6 million, marking a year-over-year increase of 4321.6%. This contributed to the annual value of $275.2 million for FY2024, which is 5844.13% up from last year.
- Latest data reveals that Dianthus Therapeutics reported Cash & Current Investments of $402.6 million as of Q3 2025, which was up 4321.6% from $257.4 million recorded in Q2 2025.
- In the past 5 years, Dianthus Therapeutics' Cash & Current Investments ranged from a high of $402.6 million in Q3 2025 and a low of $52.9 million during Q1 2023
- In the last 4 years, Dianthus Therapeutics' Cash & Current Investments had a median value of $189.9 million in 2023 and averaged $211.1 million.
- In the last 5 years, Dianthus Therapeutics' Cash & Current Investments plummeted by 6622.37% in 2023 and then skyrocketed by 61280.08% in 2024.
- Dianthus Therapeutics' Cash & Current Investments (Quarter) stood at $75.5 million in 2022, then surged by 130.12% to $173.7 million in 2023, then skyrocketed by 58.44% to $275.2 million in 2024, then surged by 46.28% to $402.6 million in 2025.
- Its Cash & Current Investments stands at $402.6 million for Q3 2025, versus $257.4 million for Q2 2025 and $263.2 million for Q1 2025.